{
  "functional_evidence_assessment": [
    {
      "variant_id": "M26I",
      "Protein_Change": {
        "ref": "L",
        "alt": "R",
        "position": "858"
      },
      "variant_string_id": "EGFR L858R",
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The study focuses on how PD-associated mutations affect cytoprotivity and protein activity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines PD-associated genomic deletions and point mutations impacting cytoprotivity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The assay used measures protein expression changes and cell phenotype effects.",
          "judgment": "Yes",
          "reasoning": "This assay directly addresses cytoprotivity changes caused by PD mutations."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Basic controls were present, and replicates were conducted.",
          "judgment": "Yes",
          "reasoning": "The paper includes basic controls and multiple replicates, indicating valid assay design."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "No direct pathogenicity evaluation was provided.",
          "judgment": "Proceed to Step 4",
          "reasoning": "The study does not provide odds/path calculation data."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "M26I reduces protein expression and cytoprotivity, supporting Pathogenic conclusions."
    },
    {
      "variant_id": "C106A",
      "Protein_Change": {
        "ref": "R",
        "alt": "H",
        "position": "1004"
      },
      "variant_string_id": "EGFR H1004R",
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The study focuses on PD-associated mutations impacting cytoprotivity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines PD-associated mutations affecting cytoprotivity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The assay measures protein expression changes and cell phenotype effects.",
          "judgment": "Yes",
          "reasoning": "This assay directly addresses cytoprotivity changes caused by PD mutations."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Basic controls were present, and replicates were conducted.",
          "judgment": "Yes",
          "reasoning": "The paper includes basic controls and multiple replicates, indicating valid assay design."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "No direct pathogenicity evaluation was provided.",
          "judgment": "Proceed to Step 4",
          "reasoning": "The study does not provide odds/path calculation data."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "C106A abolishes binding to ASK1, reducing cell death phenotype and impacting cytoprotivity."
    }
  ]
}